Bronchiolitis obliterans syndrome
Drug research and approvals for bronchiolitis obliterans syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 95 studies of bronchiolitis obliterans syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 95
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis…NCT07771855 · Phase 2 · Hopital Foch · starts Jun 24, 2026
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged…NCT07771439 · Phase 3 · Sanofi · starts Oct 12, 2026
- Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host DiseaseNCT07733141 · Not applicable · City of Hope Medical Center · starts Mar 1, 2027
- Forced Oscillatory Technique for Bronchiolitis Obliterans Syndrome After Allogeneic Bone Marrow TransplantationNCT07730931 · Not applicable · Hadassah Medical Organization · starts Aug 19, 2021
- Dry Dynamic Cupping vs Instrument-Assisted Soft Tissue Mobilization for Chronic Myofascial Low Back PainNCT07685340 · Not applicable · Ibadat International University, Islamabad · starts Jan 1, 2026
- Study of AHB-171 in Chronic Hepatitis B ParticipantsNCT07630727 · Phase 2 · Ausper Biopharma Co., Ltd. · starts Jun 24, 2026
- A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCTNCT07606703 · Phase 2 · WeiShi · starts Sep 1, 2025
- A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With…NCT07600788 · Phase 1 · Ausper Biopharma Co., Ltd. · starts Jul 9, 2026
- Dental Cleaning to Prevent Chronic Graft-Versus-Host DiseaseNCT07535008 · Not applicable · Fred Hutchinson Cancer Center · starts May 12, 2026
Phase 3 4
- IbrutinibTyrosine-protein kinase BTK inhibitor
- PrednisoneGlucocorticoid receptor agonist
- BelumosudilRho-associated protein kinase 2 inhibitor
- BudesonideGlucocorticoid receptor agonist
Phase 2 12 of 27
- RituximabB-lymphocyte antigen CD20 binding agent
- AldesleukinInterleukin-2 receptor agonist
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- ItacitinibTyrosine-protein kinase JAK1 inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- AxatilimabMacrophage colony stimulating factor receptor inhibitor
- CyclosporineCyclophilin A modulator
- MethoxsalenDNA inhibitor
- AlefaceptT-cell surface antigen CD2 inhibitor
- Bortezomib26S proteasome inhibitor
- Arsenic trioxideThioredoxin reductase 1 inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Phase 1 or earlier 10
- Efavaleukin alfa
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- GlasdegibSmoothened homolog antagonist
- LeflunomideDihydroorotate dehydrogenase inhibitor
- NilotinibTyrosine-protein kinase ABL inhibitor
- OfatumumabB-lymphocyte antigen CD20 binding agent
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- FostamatinibTyrosine-protein kinase SYK inhibitor
- .alpha.1-proteinase inhibitor humanLeukocyte elastase inhibitor
- Ivarmacitinib
How its trials ended
272 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 74 whose ending is known, 38% met their primary endpoint, 4% missed it and 58% stopped early.
- Completed, result not reported8933%
- Ongoing8029%
- Status unknown2911%
- Met its primary endpoint2810%
- Stopped: enrollment or feasibility218%
- Stopped: other or unclear145%
- Stopped: lack of efficacy41%
- Stopped: sponsor or business decision41%
- Missed its primary endpoint31%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Dec 21, 2021 | SirolimusTreatment of Bronchiolitis Obliterans Syndrome | AI Therapeutics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA